CellaVision launches digital cell morphology system into the North American Veterinary market
(Thomson Reuters ONE) -
CellaVision has decided to launch a cell morphology system for the veterinary
market in North America. The product, CellaVision ® DM96 Vet, is an adapted
version of the company's existing instrument for human blood with the capability
to analyze blood from the most common companion animals. The product will
initially be marketed to larger veterinary laboratories in the U.S. and Canada,
such as veterinary universities and commercial reference labs. The product will
be available in the first quarter, and will be sold direct by the Company.
"The veterinary market has fewer large laboratories than the human market, but
is interesting because we can sell an existing instrument with modified
software. In the larger laboratory chains in the U.S. and Canada, both the
volume of samples and the need for an efficient analytical method, are high,
which gives us opportunities for further growth in the hematology segment.
Globally the veterinary market is less consolidated as compared to the human
market, but over time, expansion outside North America is possible," says Yvonne
Mårtensson, CEO of CellaVision.
Laboratories that perform veterinary tests face the same challenges as their
human counterparts, that is, increased demand for efficiency and quality.
CellaVision's digital solution replaces a manual microscope and delivers
considerable gains in productivity, test result quality and response times.
These analyses often provide critical results used in the diagnosis of a variety
of illnesses in both humans and animals such as infection and cancer.
Hematology testing is a key component of veterinary diagnostics. In North
America, the majority of tests are from "companion animals", (i.e. Canine,
Feline and Equine), and are performed in veterinary clinics, commercial
reference laboratories or hospital laboratories. With the CellaVision DM96 Vet,
CellaVision addresses the needs of the over 100 large veterinary laboratories
throughout North America. Registration by FDA or Health Canada is not required
to sell the product in the veterinary market.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46 708 33 77 82. E-mail:yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells best-in-class systems for the routine analysis of blood and other body
fluids. These analyses often provide critical results used in the diagnosis of a
variety of illnesses such as infection and cancer. CellaVision's products reduce
manual laboratory work, standardize results and support an efficient laboratory
workflow. The company has leading-edge expertise in digital image analysis,
artificial intelligence and automated microscopy. In 2010, net sales were 132
MSEK and sales continue to grow with the target to increase by at least 15
percent per year over an economic cycle. CellaVision has its head office in
Lund, Sweden, and subsidiaries in the US, Canada and Japan. The company share is
listed on Nasdaq OMX Stockholm, Small Cap. Read more atwww.cellavision.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1582424]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.02.2012 - 04:02 Uhr
Sprache: Deutsch
News-ID 1079263
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Lund
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 57 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision launches digital cell morphology system into the North American Veterinary market
"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
